NCT05489679View on ClinicalTrials.gov

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions
Breast Cancer
Interventions
DRUG

AC682

Participants will receive AC682 by mouth daily in 28-day cycles.

Trial Locations (3)

Unknown

Site 1001, Beijing

Site 1003, Hangzhou

Site 1002, Tianjin

Sponsors
All Listed Sponsors
lead

Accutar Biotechnology Inc

INDUSTRY

NCT05489679 - A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter